This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2019 Remove HIV Treatment and Prevention Agents Remove Packaging Related Topics
Dosage Documentation Pharmaceutical Companies Immunization Vaccines FDA Pharmaceutical Companies More Related Topics >
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

APRIL 25, 2023

In 2019, Mallinckrodt entered into a collaboration agreement with Silence Therapeutics to develop and commercialize RNAi therapeutics to treat life-threatening unmet diseases. Through the 2019 agreement, Mallinckrodt received the exclusive worldwide license to Silence’s SLN500. R&D Expenditure: $85.1M

HIV Treatment and Prevention Agents 40
HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40
article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

JULY 6, 2023

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Vertex continued to invest in CM with two additional approved drugs—Symdeco/Symkevi in 2018 and Trikafta in 2019—with the same indication. 8 (November/December 2019):26–29.

HIV Treatment and Prevention Agents 52
HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024